PHA Names New President and CEO, Matt Granato

PHA Names New President and CEO, Matt Granato
3.7
(6)

Matt J. Granato is the newly named president and CEO of the Pulmonary Hypertension Association (PHA), the nonprofit group announced.

Granato, who has more than 20 years of experience working in nonprofits and healthcare associations, will assume this office and its duties on Jan. 4.

He is the third president and CEO of PHA in its 30-year history. Launched in 1991 by patients and a caregiver, the group’s goal is to build a community of support, as well as to foster education and support research into pulmonary hypertension (PH).

“PHA’s mission to extend and improve the lives of patients and their families has been a common thread throughout my career, and I am honored to work toward that goal as PHA’s next president and CEO,” Granato said in a press release.

“I look forward to working with a talented group of professionals and committed volunteer leaders, and especially with patients and their families, to make a difference in the lives of those affected by PH,” he added.

For the past four years, Granato served as the CEO of the Society for Maternal-Fetal Medicine (SMFM), which focuses on helping people with high-risk pregnancies. There, he worked to meet the needs of both healthcare providers and their patients.

As a CEO, he led a strategic plan that emphasized advocacy, research, and education. The effort resulted in a membership growth of 52%, and record-breaking attendance at the SMFM’s 2019 Annual Meeting. Previously, Granato served as the executive director for an association of college health centers, and worked for a transfusion medicine trade association.

“We are thrilled to welcome Matt Granato to PHA,” said Colleen Brunetti, chair of the PHA’s board of trustees. “Matt brings to the organization an impressive resume and skill set, along with a 21st-century leadership style that will help us grow our mission, support our staff and lead us into our 30th anniversary year with a clear vision for success and progress.”

Through his leadership, she added, the PHA “is poised for continued success.”

Granato succeeds Brad A. Wong as CEO of PHA, whose term began in 2016 and expires at year’s end. Under Wong’s direction, the PHA continued to promote patient care and research, raise awareness of the disease, and amplify the voice of people with PH.

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.
Total Posts: 330
Patrícia holds her PhD in Medical Microbiology and Infectious Diseases from the Leiden University Medical Center in Leiden, The Netherlands. She has studied Applied Biology at Universidade do Minho and was a postdoctoral research fellow at Instituto de Medicina Molecular in Lisbon, Portugal. Her work has been focused on molecular genetic traits of infectious agents such as viruses and parasites.
×
Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.
Latest Posts
  • PHA names president, CEO
  • bosentan
  • Sotatercept, exercise capacity

How useful was this post?

Click on a star to rate it!

Average rating 3.7 / 5. Vote count: 6

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?